Clinical studies with the anti-CD37 agents otlertuzumab (TRU-016) [12], IMGN529 [13], and AGS67E [14] suggest that targeting CD37 is a viable therapeutic strategy, with evidence of anti-tumor activity seen in patients with DLBCL, FL and other B cell NHLs. This evidence concerns the gene CD37 and B-cell non-Hodgkin lymphoma.